CVE:VM Voyageur Pharmaceuticals (VM) Stock Price, News & Analysis C$0.19 0.00 (0.00%) As of 05/2/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Voyageur Pharmaceuticals Stock (CVE:VM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VM alerts:Sign Up Key Stats Today's RangeC$0.19▼C$0.1950-Day RangeC$0.14▼C$0.2052-Week RangeC$0.04▼C$0.25Volume50,750 shsAverage Volume212,835 shsMarket CapitalizationC$28.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVoyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada.Read More… Receive VM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyageur Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VM Stock News HeadlinesVoyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study ResultsApril 24, 2025 | finance.yahoo.comVoyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market LaunchApril 1, 2025 | finance.yahoo.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 3, 2025 | Stansberry Research (Ad)Voyageur Pharmaceuticals Ltd.: Voyageur Clarifies Terms of Previously Announced AgreementMarch 3, 2025 | finanznachrichten.deVoyageur Advances MRI Drug Development Using Next Generation Endohedral FullerenesFebruary 18, 2025 | finance.yahoo.comVoyageur Pharmaceuticals With CEO, Brent Willis | February 6th, 2025February 6, 2025 | msn.comVoyageur Receives $600K Grant From Alberta Innovates for Product DevelopmentFebruary 6, 2025 | finance.yahoo.comVoyageur Secures $687k of Additional Capital From Warrant ExercisesJanuary 24, 2025 | finance.yahoo.comSee More Headlines VM Stock Analysis - Frequently Asked Questions How have VM shares performed this year? Voyageur Pharmaceuticals' stock was trading at C$0.09 on January 1st, 2025. Since then, VM shares have increased by 123.5% and is now trading at C$0.19. View the best growth stocks for 2025 here. How do I buy shares of Voyageur Pharmaceuticals? Shares of VM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Voyageur Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyageur Pharmaceuticals investors own include GFG Resources (GFG), Pine Cliff Energy (PNE), Tamarack Valley Energy (TVE), Caladrius Biosciences (CLBS), Capstone Copper (CS), Calibre Mining (CXB) and Mawson Gold (MAW). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:VM CIKN/A Webwww.voyageurminerals.ca Phone587-779-6166FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-1,664,938.27 Net MarginsN/A Pretax MarginN/A Return on Equity-117.77% Return on Assets-30.77% Debt Debt-to-Equity Ratio4.23 Current Ratio0.10 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow35.00 Book ValueC$0.01 per share Price / Book28.04Miscellaneous Outstanding Shares151,517,550Free FloatN/AMarket CapC$28.79 million OptionableNot Optionable Beta0.32 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (CVE:VM) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyageur Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyageur Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.